In recent years multipotent haematopoietic stem cell (HSC) therapy has become a popular technique with a range of promising health benefits. A broad variety of possibilities makes this cutting-edge therapy a turning point in modern medicine. One of the recognized challenges is the ability to quickly obtain a sufficient number of desired cell types for transplantation, with high purity. Today, the time-consuming sample preparation steps and the considerable loss of cells during the process are still significant challenge. The MARS platform addresses it through an easy method to isolate CD34+ cells from mobilized blood without RBC lysis and density gradient centrifugation.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
We divide cookies into necessary cookies and third-party cookies that relate to functionality, technical issues and the collection of statistical and marketing data. No consent to third-party cookies allows you to continue using the website.
If you are looking for more information, we invite you to read our privacy policy.